rupiya.io
⠋Loading...
0%
❯ Fetching dividend history...
Dr Reddy's Labs is a leading Indian company in the Pharmaceuticals space, listed on the NSE. The company is a key player in the Pharma — Formulations segment with a strong market position and diversified operations.
Dr Reddys Laboratories Ltd makes money through Core Business, Other Segments, Exports in Pharma — Formulations. Revenue quality depends on demand growth, margin discipline, balance-sheet strength, and the company's ability to defend its position within Pharma.
Create a free account to view momentum, moving averages, and delivery signals.
Upgrade to view volatility, drawdown, factor, and risk metrics.
| Metric | 1 Year | 3 Years | 5 Years | 10 Years |
|---|---|---|---|---|
| Sales | — | — | — | — |
| Profit | — | — | — | — |
| Stock Price | — | — | — | — |
| ROE | — | — | — | — |
| Period | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | ₹15,023 Cr | ₹15,568 Cr | ₹14,196 Cr | ||||||||
| Expenses | ₹11,515 Cr |
| Quarter | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | ₹6,315 Cr | ₹6,758 Cr | ₹6,903 Cr | ₹7,237 Cr | ||||||||
| Expenses | ₹4,781 Cr | ₹4,696 Cr | ₹4,894 Cr | ₹5,214 Cr | ||||||||
| Operating Profit | ₹1,534 Cr | ₹2,062 Cr | ₹2,008 Cr | ₹2,023 Cr |
| Period | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Liabilities | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Equity Capital | ₹85 Cr | ₹85 Cr | ₹83 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Reserves | ₹9,768 Cr | ₹12,484 Cr | ₹12,179 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Period | Operating | Investing | Financing | Net Cash Flow |
|---|---|---|---|---|
| Mar 2016 | ₹2,524 Cr | ₹-2,370 Cr | ₹-433 Cr | — |
| Mar 2017 | ₹3,263 Cr | ₹-1,610 Cr | ₹-1,700 Cr | — |
| Mar 2018 | ₹2,144 Cr | ₹-1,890 Cr | ₹-369 Cr | — |
| Mar 2019 | ||||
| Mar 2020 | ||||
| Mar 2021 | ||||
| Mar 2022 |
| Ratio | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 | FY10 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE % | 11.7% | 11.3% | 10.4% | — | — | — | — | — | — | — | — | — | — | — | — |
| ROCE % | 12.9% | 12.6% | 11.7% | — | — | — | — | — | — | — | — | — | — | — | — |
| Debt/Equity | 0.5 | 0.6 | 0.5 | — | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | 11.7 | 13.2 | 8.7 | — | — | — | — | — | — | — | — | — | — | — |
| Year | Type | Amount (₹) |
|---|---|---|
| FY24 | Final | ₹4.27 |
| FY23 | Final | ₹17.67 |
| FY22 | Final | ₹12.11 |
| FY21 | Interim | |
| FY20 | Final | |
| FY19 | Final |
No corporate actions recorded.
| Company | M.Cap | P/E | ROE | 1Y Return |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | ₹4,51,075 Cr | 41.3 | 0.00% | +8.45% |
| Cipla Ltd | ₹1,15,638 Cr | 25.5 | +11.74% | -5.78% |
| Apollo Hospitals Enterprise Ltd | ₹1,16,201 Cr | 64.5 | 0.00% | +7.74% |
| Divis Laboratories Ltd | ₹1,79,486 Cr | 72.5 | 0.00% | +3.69% |
| Torrent Pharmaceuticals Ltd | ₹1,49,446 Cr | 69.7 | 0.00% | +15.25% |
Create a free account to see institutional ownership snapshots.
Create a free account to view recent director and promoter trades.
Create a free account to view recent institutional deal activity.
Create a free account to view analyst estimate summaries.
Create a free account to view ESG risk and governance summaries.
Upgrade to view issuer ratings, instruments, outlooks, and rating history.
rupiya.io is for research and education only. Metrics shown are not investment advice. Validate with SEBI-regulated disclosures before acting.
Deep-dive analysis of Dr Reddy's Labs's competitive moat, management quality, and growth runway available with Premium.
Premium| ₹11,983 Cr |
| ₹11,724 Cr |
| Operating Profit | ₹3,508 Cr | ₹3,585 Cr | ₹2,472 Cr |
| OPM % | 23.0% | 23.0% | 17.0% |
| Other Income | ₹260 Cr | ₹295 Cr | ₹172 Cr |
| Depreciation | ₹760 Cr | ₹939 Cr | ₹1,027 Cr |
| Interest | ₹108 Cr | ₹83 Cr | ₹63 Cr |
| Profit Before Tax | ₹2,900 Cr | ₹2,859 Cr | ₹1,554 Cr |
| Tax | ₹2,900 Cr | ₹2,859 Cr | ₹1,554 Cr |
| Net Profit | ₹2,336 Cr | ₹2,131 Cr | ₹1,292 Cr |
| EPS (₹) | 27.4 | 25.0 | 15.6 |
| Dividend Payout % | 15% | 16% | 26% |
Register free to see 8 more years.
| OPM % | 24.0% | 31.0% | 29.0% | 28.0% |
| Depreciation | ₹316 Cr | ₹353 Cr | ₹376 Cr | ₹374 Cr |
| Interest | ₹35 Cr | ₹37 Cr | ₹35 Cr | ₹39 Cr |
| Net Profit | ₹960 Cr | ₹1,405 Cr | ₹1,482 Cr | ₹1,381 Cr |
| EPS (₹) | 11.5 | 16.9 | 17.8 | 16.6 |
Register free to see 8 more quarters.
| Borrowings | ₹4,314 Cr | ₹3,352 Cr | ₹4,918 Cr |
| Other Liabilities | ₹4,290 Cr | ₹4,408 Cr | ₹4,474 Cr |
| Total Liabilities | ₹18,457 Cr | ₹20,330 Cr | ₹21,654 Cr |
| Assets |
| Fixed Assets | ₹5,377 Cr | ₹6,563 Cr | ₹6,931 Cr |
| Investments | ₹2,248 Cr | ₹3,833 Cr | ₹2,110 Cr |
| Receivables | — | — | — |
| Inventory | — | — | — |
| Cash & Equivalents | — | — | — |
| Other Assets | ₹10,303 Cr | ₹9,162 Cr | ₹9,290 Cr |
| Total Assets | ₹18,457 Cr | ₹20,330 Cr | ₹21,654 Cr |
Register free to see 8 more years.
| Mar 2023 |
| Mar 2024 |
| Mar 2025 |
| Mar 2026 |
Register free to see 8 more years.
| — |
| Current Ratio | 1.6 | 1.8 | 1.7 | — | — | — | — | — | — | — | — | — | — | — | — |
| Quick Ratio | 1.2 | 1.2 | 1.1 | — | — | — | — | — | — | — | — | — | — | — | — |
| OPM % | 14.7% | 14.5% | 13.2% | — | — | — | — | — | — | — | — | — | — | — | — |
| NPM % | 8.8% | 8.7% | 7.9% | — | — | — | — | — | — | — | — | — | — | — | — |
| EV/EBITDA | 13.2 | 17.3 | 13.6 | — | — | — | — | — | — | — | — | — | — | — | — |
| PEG Ratio | 1.9 | 1.5 | 1.4 | — | — | — | — | — | — | — | — | — | — | — | — |
| Asset Turnover | 1.3 | 0.7 | 0.9 | — | — | — | — | — | — | — | — | — | — | — | — |
| Inventory Turnover | 10.8 | 5.8 | 5.0 | — | — | — | — | — | — | — | — | — | — | — | — |
Register free to see 12 more years of ratio trends.